Analysis and comparison of the cost‐effectiveness of statins according to the baseline low‐density lipoprotein cholesterol level in Korea. (1st March 2017)

• Record Type: Journal Article
• Authors: Jeong, Y. J.; Kim, H.; Baik, S. J.; Kim, T. M.; Yang, S. J.; Lee, S.‐H.; Cho, J.‐H.; Lee, H.; Yim, H. W.; Choi, I. Y.; Yoon, K.‐H.; Kim, H.‐S.
• Is Part Of: Journal of clinical pharmacy and therapeutics. Volume 42:Number 3(2017)
• Page Start: 292
• Page End: 300
• Publication Date: 2017-03-01
• Subjects: cost‐effectiveness -- HMG‐CoA reductase inhibitor -- statin; Clinical pharmacology -- Periodicals; Chemotherapy -- Periodicals; 615
• DOI: 10.1111/jcpt.12512
• Languages: English
• ISSNs: 0269-4727

Abstract

Summary: What is known and objective: There are a few Korean studies on the economics of statins based on reduction in low‐density lipoprotein cholesterol (LDL‐C) data from other countries. This study aimed to analyse and compare the cost‐effectiveness of statins according to the baseline LDL‐C level in Korea. Methods: Between January 2009 and December 2015, the data of patients who were prescribed statins for the first time were extracted from electronic medical records. We performed a cost‐effectiveness analysis (CEA) based on the LDL‐C reduction rate (CEA‐RR) and target achievement rate. Results and discussion: Among high‐intensity statins, the CEA‐RR value of rosuvastatin (20 mg) was significantly lower than that of atorvastatin (40 mg) at all baseline LDL‐C levels, except levels of 160–189 mg/dL. Additionally, at baseline LDL‐C levels of 130–159 mg/dL, the CEA‐RR value of rosuvastatin (20 mg) was three times lower than that of atorvastatin (40 mg) (9·1 ± 2·5 $/% vs. 31·7 ± 15·0 $/%, P < 0·001). Among moderate‐to‐low‐intensity statins, rosuvastatin (5 mg) showed the lowest CEA‐RR value (4·0 ± 0·6 $/%), and the value significantly increased for pitavastatin (2 mg) (8·0 ± 0·6 $/%), atorvastatin (10 mg) (9·5 ± 0·5 $/%), simvastatin (10·8 ± 1·1 $/%) and pravastatin (40 mg) (11·5 ± 0·9 $/%) in order ( P < 0·0001). On changing from atorvastatin (10 mg) to atorvastatin (20 mg), the additional yearly cost was 16·0 and additional CEA‐RR value was 2·74 $/%. On the other hand, on changing from atorvastatin (10 mg) to rosuvastatin (10 mg), the additional yearly cost was −16·3 and additional CEA‐RR value was −1·8 $/ %. What is new and conclusion: We successfully compared the cost‐effectiveness of statins according to the baseline LDL‐C level in Korea. It is expected that our findings will help clinical decision‐making with regard to statin prescription, and this will help reduce national medical expenditure. Abstract : Among high‐intensity statins, the CEA‐RR value of rosuvastatin (20 mg) was significantly lower than that of atorvastatin (40 mg). Among moderate‐to‐low‐intensity statins, rosuvastatin (5 mg) showed the lowest CEA‐RR value (4.0 ± 0.6 $/%). On changing from atorvastatin (10 mg) to atorvastatin (20 mg), the additional yearly cost was 16.0 $ and additional CEA‐RR value was 2.74 $/%.